FDI in Pharmaceuticals: Greenfield vs Brownfield Route Differences
India wants foreign capital building new pharmaceutical manufacturing capacity far more than it wants foreign capital simply buying control of existing domestic drugmakers — and the FDI policy encodes that preference directly into two very different approval pathways depending on which one an investor is actually doing.
Greenfield pharma: the fully open route
Greenfield projects — setting up a new pharmaceutical manufacturing or research facility from scratch — are eligible for 100% FDI under the automatic route, meaning no prior government approval is required, only post-investment reporting compliance. This reflects a policy priority: foreign capital that adds genuinely new manufacturing capacity, jobs, and (often) technology transfer is treated as unambiguously beneficial.
Brownfield pharma: a materially different pathway
Brownfield investment — acquiring or investing in an existing pharmaceutical company (whether through acquisition of an existing manufacturer, or a foreign investor taking a stake in an already-operating Indian pharma business) — is treated more cautiously:
- Up to 74% FDI is permitted under the automatic route.
- FDI beyond 74% and up to 100% requires government approval.
Why the distinction exists
The policy concern behind the brownfield restriction is less about the transaction size and more about outcomes seen in some prior acquisitions of Indian generic drug manufacturers by multinational pharmaceutical companies — concerns have included potential impacts on the availability of affordable generic medicines, reduced domestic R&D investment post-acquisition, and product-mix shifts away from essential/low-margin drugs after a change of control. The government-approval requirement beyond 74% gives the administrative ministry a checkpoint to review these considerations for full/majority foreign acquisitions of established Indian pharma businesses, without blocking foreign capital from meaningfully participating (up to 74% automatically) or from freely building new capacity (greenfield, 100% automatic).
What counts as greenfield vs brownfield in practice
| Scenario | Classification |
|---|---|
| Setting up a new manufacturing plant with no prior existing Indian pharma operations | Greenfield |
| Acquiring shares in an existing, already-operating Indian pharmaceutical company | Brownfield |
| A greenfield JV that later also acquires an existing facility | Requires careful, transaction-specific classification — often assessed component by component |
What this means for deal structuring
A foreign pharma investor evaluating an Indian target should factor the government-approval timeline into the deal timetable if the intended stake exceeds 74% — this is a materially different process than a straightforward automatic-route acquisition, and getting the classification (greenfield vs brownfield) wrong at the term-sheet stage can derail an otherwise-agreed transaction structure.